

# Xpert® vanA/vanB

*Rapid detection of vanA and vanB resistance genes in 48 minutes for effective infection control strategies to prevent VRE outbreaks*



## The Need

- Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities<sup>1</sup>
- In healthcare settings, colonized patients and environmental contamination contribute to VRE spread<sup>1</sup>
- High-risk patients colonized with VRE have 24 times the increased infection risk<sup>2</sup>
- Infections caused by VRE are associated with high mortality<sup>3</sup>
- VRE has an impact on patient length of stay, and in turn, hospitalization costs<sup>3</sup>

## The Solution

- The **Xpert vanA/vanB** test is a rapid and accurate method for detection of VRE colonization among high-risk admissions and for screening during outbreaks of VRE
- Fast, active screening of high-risk patients to prevent the spread of VRE and better manage colonization in healthcare settings

## The Impact

- The **Xpert vanA/vanB** test facilitates more efficient infection control surveillance programs:<sup>4</sup>
  - 93% reduction of turn around time from 70.5h with chromogenic agar culture to 4.6h
  - High negative predictive value allows for better management of non-colonized patients
  - Decreased the number of contact patients thereby preventing VRE transmission
  - 94% reduction in overall cost (€14,302 with culture vs €870)
- Compared to culture, faster time to result may support more effective patient management: more isolation and transmission risk days saved<sup>5</sup>
  - 141 saved isolation days and 292 saved transmission risk days

1 Levitus M, et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. [https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#\\_NBK513233\\_pubdet](https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet). Accessed December 11, 2023

2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.

3 Eichel V, M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128

4 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control. 2013 Nov; 2:30.

5 Holzknacht BJ, Hansen DS, Nielsen L, Kailow A, Jarlov JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59



# Xpert® vanA/vanB

## Product Reference Sheet — CE-IVD

<b>Test Reagent Kit</b>	Xpert vanA/vanB	
<b>Catalog Number</b>	GXVANA/B-CE-10	
<b>Technology</b>	Real-time RT-PCR	
<b>Targets</b>	vanA, vanB	
<b>Batch or On-Demand</b>	On-Demand	
<b>Minimum Batch Size</b>	1	
<b>Sample Type</b>	Rectal or perianal swab	
<b>Sample Extraction</b>	Automated/integrated	
<b>Precision Pipetting</b>	Not required	
<b>TAT</b>	48 minutes	
<b>Controls: Process</b>	Sample Processing Control (PCC)	
<b>Controls: Probe Function/Detection</b>	Probe Check Control (SPC)	
	<b>Rectal</b>	<b>Perianal</b>
<b>Sensitivity</b>	99%	92.9%
<b>Specificity</b>	79.3%	88.7%
<b>Sample Stability</b>	Swabs in transport tube 2–8 °C for 5 days	
<b>Kit Storage</b>	2–28 °C	
<b>Commercial Controls</b>	Refer to Package Insert or Contact Cepheid Technical Support	

Xpert® vanA/vanB Package Insert n° 301-0188 Rev. F March 2023  
CE-IVD. *In Vitro* Diagnostic Medical Device. May not be available in all countries. Not available in the United States.

### CORPORATE HEADQUARTERS

904 Caribbean Drive  
Sunnyvale, CA 94089 USA

TOLL FREE +1.888.336.2743  
PHONE +1.408.541.4191  
FAX +1.408.541.4192

### EUROPEAN HEADQUARTERS

Vira Solelh  
81470 Maurens-Scopont France

PHONE +33.563.82.53.00  
FAX +33.563.82.53.01  
EMAIL [cepheid@cepheideurope.fr](mailto:cepheid@cepheideurope.fr)

[www.Cepheidinternational.com](http://www.Cepheidinternational.com)

© 2024 Cepheid. 3358-01

